Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal)

Technology appraisal guidance
Published: 16 January 2023
www.nice.org.uk/guidance/ta859
## Contents

Advice........................................................................................................................................ 3

Information.................................................................................................................................. 3
Advice

NICE is unable to make a recommendation about the use in the NHS of angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock. This is because Paion AG has confirmed that it does not intend to make an evidence submission for the appraisal. Paion AG considers that there are likely low numbers of people who would be eligible for treatment because of the likely positioning in the treatment pathway for this condition.

Information

If NHS organisations wish to consider angiotensin II for this indication, they should follow the advice on rational local decision making in the NHS Constitution for England and the NHS Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012. This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-4967-0